Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ibrexafungerp in Healthy Lactating Women
NCT06954493Phase 1Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jul 2023
- Primary completion
- Nov 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrexafungerp in vulvovaginal candidiasis (VVC), sponsored by SCYNEXIS, Inc. Primary endpoints: SCY-078 Breast Milk Concentrations and SCY-078 Plasma Concentrations. Started Jul 2023; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT06954493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954493.